Skip to main content
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

25I-NBMD

25I-NBMD molecule structure25I-NBMD molecule structure
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2,3-methylenedioxybenzyl)ethanamine
NBMD-2C-I, Cimbi-29
Psychoactive Class
Chemical Class

25I-NBMD is a synthetic psychedelic of the substituted phenethylamine class, specifically an N-benzylated derivative of 2C-I.1 It was discovered in 2006 by a research team led by David Nichols at Purdue University. Closely related to the 25X-NBOMe series, it is a highly potent compound that acts as a partial agonist at the 5-HT2A receptor.citation needed As a research chemical, it has very limited documentation regarding its effects and safety profile in humans.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~800 µg
Light800-1500 µg
Moderate1500-2000 µg
Strong2000-3000 µg
Heavy3000+ µg

Duration

Onset20-40 minutes
After Effects1-8 hours
Total4-6 hours

Subjective Effects

Subjective Effects not written up yet

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)
white → brown2 → green2 → green3
Mecke(ME)
white → brown2 → black3
Mandelin(MD)
yellow2 → brown2 → black3
Liebermann(LB)
white → brown2 → black3
Powered by PROtestkit.eu

Pharmacology

Pharmacodynamics

25I-NBMD acts as a potent partial agonist at the serotonin 5-HT2A receptor, with a reported Ki of 0.049 nM at the human 5-HT2A receptor. It is a derivative of the phenethylamine hallucinogen 2C-I, featuring an N-benzyl substitution with a methylenedioxy group.1

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Cross Tolerance

Serotonergic psychedelics, 5-HT2A agonists

Harm Potential

Toxicity

Lethal Dosage

No lethal-dose or LD50 data were identified. Avoiding other psychedelics, stimulants, and redosing is advised.

History & Culture

25I-NBMD was discovered in 2006 by a research team at Purdue University led by David Nichols.citation needed The compound is a derivative of the phenethylamine hallucinogen 2C-I, developed as part of ongoing investigations into serotonin receptor pharmacology.

Legality

International

The complete current official Yellow, Green, and Red Lists contain no listing for 25I-NBMD, NBMD-2C-I, or Cimbi-29. The Green List separately lists 25I-NBOMe in Schedule I as 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; that distinct listing does not establish international scheduling of 25I-NBMD.

By Country

Illegal8
Canada flagCanadaIllegal
Finland flagFinlandIllegal
Germany flagGermanyIllegal (analog/blanket ban)
Netherlands flagNetherlandsIllegal (analog/blanket ban)
Poland flagPolandIllegal
Sweden flagSwedenIllegal
Ukraine flagUkraineIllegal (analog/blanket ban)
United Kingdom flagUnited KingdomIllegal (analog/blanket ban)

References

Source Pages

  1. PsychonautWiki: 25I-NBOMe (similar compound)
  2. TripSit: 25I-NBMD Factsheet
  3. Wikipedia

Citations

  1. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. (n.d.). https://pmc.ncbi.nlm.nih.gov/articles/PMC3866097/12
  2. Controlled Drugs and Substances Act — Schedule III, item 35. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-10.html1
  3. Controlled Drugs and Substances Act — section 4. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-1.html1
  4. Government Decree on psychoactive substances banned from the consumer market (1130/2014), appendix, consolidated through amendment 650/2026. finlex.fi (n.d.). https://finlex.fi/api/media/statute-consolidated/1074839/media/8500.pdf1
  5. Government Decree on psychoactive substances banned from the consumer market (1130/2014), appendix, consolidated through amendment 650/2026. finlex.fi (n.d.). https://www.finlex.fi/api/media/statute/894482/mainPdf/main.pdf1
  6. Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1 Nr. 1 und § 3. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/anlage_1.html1
  7. Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1 Nr. 1 und § 3. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__3.html1
  8. Opiumwet. wetten.overheid.nl (n.d.). https://wetten.overheid.nl/BWBR0001941/1
  9. PubChem 25I-NBMD compound record. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/25I-NBMD/property/CanonicalSMILES,IUPACName/JSON1
  10. Obwieszczenie Ministra Zdrowia z dnia 17 czerwca 2024 r. w sprawie ogłoszenia jednolitego tekstu rozporządzenia Ministra Zdrowia w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (Dz.U. 2024 poz. 1139). eli.gov.pl (n.d.). https://eli.gov.pl/api/acts/DU/2024/1139/text.html1

Further Reading

  1. Brandt SD et al. 'Analytical profile of NBOMe and NBMD designer psychedelics'. Drug Testing & Analysis 2014.
  2. Ettrup A et al. 'Radiosynthesis and in vivo evaluation of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers'. European Journal of Nuclear Medicine 2011.
  3. Helander A & Beck O. ‘NBOMe and related substances: a review’. Curr Top Behav Neurosci 2016.
  4. Helander A & Beck O. 'NBOMe and related substances: a review'. Current Topics in Behavioral Neuroscience 2016.
  5. Nikolaou P et al. 'Headspace: A report on 25I-NBMD intoxication'. Journal of Analytical Toxicology 2015.
  6. Reddit: user reports compilation – r/ResearchChemicals search “25I-NBMD” (accessed 2025-08-02)

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 25I-NBMD article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.